Pancreatic ductal adenocarcinoma is a stroma-rich and highly challenging cancer to treat. Over recent years, it has become increasingly evident that the complex network of soluble cytokines, growth factors, proteases, and components of the extracellular matrix collaboratively interact within the tumor microenvironment, sustaining and driving cancer cell proliferation, invasion, and early metastasis. More recently, the tumor microenvironment has also been appreciated to mediate therapeutic resistance in pancreatic ductal adenocarcinoma, thus opening numerous avenues for novel therapeutic explorations. Inert and soluble components of the tumor stroma have been targeted in order to break down the extracellular matrix scaffold, relieve vessel c...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer characterized by multiple molecular alter...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer type, which is projected to become t...
Introduction: Pancreatic cancer represents around 3% of all cancers in the United States. Despite th...
Pancreatic cancers are among the most ominous, and among the most studied. Their complexities have p...
The stroma-rich, immunosuppressive microenvironment is a hallmark of pancreatic ductal adenocarcinom...
AbstractPancreatic cancer is one of the most lethal malignancies. Significant progresses have been m...
Pancreatic ductal adenocarcinoma (PDAC) is an intractable cancer and a leading cause of cancer death...
Pancreatic cancer is accompanied by a fibrotic reaction that alters interactions between tumor cells...
Abstract Despite a few breakthroughs in therapy for advanced disease in the recent years, pancreatic...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer generally refracto...
Pancreatic ductal adenocarcinoma (PDA) exhibits one of the poorest prognosis of all solid tumours an...
Pancreatic cancer is one of the deadliest cancers worldwide, largely due to its aggressive developme...
Pancreatic ductal adenocarcinoma (PDAC) is projected to emerge as the second leading cause of cancer...
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest malignancies among all cancers. Desp...
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth ...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer characterized by multiple molecular alter...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer type, which is projected to become t...
Introduction: Pancreatic cancer represents around 3% of all cancers in the United States. Despite th...
Pancreatic cancers are among the most ominous, and among the most studied. Their complexities have p...
The stroma-rich, immunosuppressive microenvironment is a hallmark of pancreatic ductal adenocarcinom...
AbstractPancreatic cancer is one of the most lethal malignancies. Significant progresses have been m...
Pancreatic ductal adenocarcinoma (PDAC) is an intractable cancer and a leading cause of cancer death...
Pancreatic cancer is accompanied by a fibrotic reaction that alters interactions between tumor cells...
Abstract Despite a few breakthroughs in therapy for advanced disease in the recent years, pancreatic...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer generally refracto...
Pancreatic ductal adenocarcinoma (PDA) exhibits one of the poorest prognosis of all solid tumours an...
Pancreatic cancer is one of the deadliest cancers worldwide, largely due to its aggressive developme...
Pancreatic ductal adenocarcinoma (PDAC) is projected to emerge as the second leading cause of cancer...
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest malignancies among all cancers. Desp...
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth ...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer characterized by multiple molecular alter...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer type, which is projected to become t...
Introduction: Pancreatic cancer represents around 3% of all cancers in the United States. Despite th...